Overview

Our MAGE-A4 SPEAR T-cell therapy is directed to a member of the MAGE-A family of cancer testis antigens expressed in a number of solid tumor cell types. The MAGE-A4 antigen is among the most commonly expressed cancer testis antigens. The clinical study for our MAGE-A4 SPEAR T-cell is a phase I, open label, dose escalation study designed to evaluate the safety and anti-tumor activity in certain patients with urothelial (bladder) cancers, melanoma, head and neck cancer, ovarian cancer, NSCLC, esophageal cancer, gastric cancers, synovial sarcoma, and MRCLS1.

Pipeline

Program Indications Pre-Clinical Phase I/II Registration
MAGE-A4 Urothelial
Melanoma
Ovarian
NSCLC (lung)
Esophegeal
Gastric
Synovial Sarcoma
MRCLS 1
Pre-Clinical Phase complete
Phase I/II Phase in progress
Registration Phase not started
  1. MRCLS = myxoid/round cell liposarcoma